Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Somatropin in Japanese Participants with Prader-Willi Syndrome
2024-000101-32Phase 3
- Sponsor
- Pfizer
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin in Prader-Willi syndrome (PWS), sponsored by Pfizer. Primary endpoint: Change in lean body mass by DEXA.
02
Drugs
somatropin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2024-000101-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000101-32.